ProMIS Neurosciences logo

ProMIS NeurosciencesNASDAQ: PMN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

10 January 2007

Next earnings report:

01 April 2025

Last dividends:

N/A

Next dividends:

N/A
$32.60 M
-53%vs. 3y high
30%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:44:51 GMT
$1.00-$0.01(-1.27%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PMN Latest News

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
globenewswire.com14 November 2024 Sentiment: POSITIVE

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential target engagement in patients with Alzheimer's disease

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference
globenewswire.com30 October 2024 Sentiment: POSITIVE

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for year-end 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented positive results from all five cohorts from the Phase 1a, single ascending dose clinical trial of its lead product candidate, PMN310, at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place from October 29 – November 1, 2024 in Madrid, Spain. PMN310 is an investigational humanized monoclonal antibody (mAb) designed and developed to selectively target soluble amyloid beta oligomers (AβOs), which ProMIS believes to be the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
globenewswire.com12 September 2024 Sentiment: POSITIVE

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that preclinical data supporting the potential role of its lead product candidate, PMN310, as a treatment for AD will be highlighted in an oral presentation at the 4th International Conference on Cognitive & Behavioral Neurosciences (ICBN) taking place from September 12-13, 2024 in Lisbon, Portugal.

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
globenewswire.com01 August 2024 Sentiment: POSITIVE

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim Chief Executive Officer of ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024 at 12:00 p.m. ET.

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
globenewswire.com26 July 2024 Sentiment: POSITIVE

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer's disease patients

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewsWire06 September 2023 Sentiment: POSITIVE

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 4:30 p.m. ET in New York, NY.

What type of business is ProMIS Neurosciences?

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

What sector is ProMIS Neurosciences in?

ProMIS Neurosciences is in the Healthcare sector

What industry is ProMIS Neurosciences in?

ProMIS Neurosciences is in the Biotechnology industry

What country is ProMIS Neurosciences from?

ProMIS Neurosciences is headquartered in Canada

When did ProMIS Neurosciences go public?

ProMIS Neurosciences initial public offering (IPO) was on 10 January 2007

What is ProMIS Neurosciences website?

https://www.promisneurosciences.com

Is ProMIS Neurosciences in the S&P 500?

No, ProMIS Neurosciences is not included in the S&P 500 index

Is ProMIS Neurosciences in the NASDAQ 100?

No, ProMIS Neurosciences is not included in the NASDAQ 100 index

Is ProMIS Neurosciences in the Dow Jones?

No, ProMIS Neurosciences is not included in the Dow Jones index

When was ProMIS Neurosciences the previous earnings report?

No data

When does ProMIS Neurosciences earnings report?

The next expected earnings date for ProMIS Neurosciences is 01 April 2025